CN102000099B - Medicine for treating breast cancer and preparation method thereof - Google Patents
Medicine for treating breast cancer and preparation method thereof Download PDFInfo
- Publication number
- CN102000099B CN102000099B CN2010105637573A CN201010563757A CN102000099B CN 102000099 B CN102000099 B CN 102000099B CN 2010105637573 A CN2010105637573 A CN 2010105637573A CN 201010563757 A CN201010563757 A CN 201010563757A CN 102000099 B CN102000099 B CN 102000099B
- Authority
- CN
- China
- Prior art keywords
- medicine
- oxygen
- diene
- ursol
- grams
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a medicine for treating breast cancer and a preparation method thereof. The medicine is prepared from effective medicinal components and medicinal adjuvant in proportion by weight, wherein the effective medicinal components comprise 3 beta-oxygen-alpha-L arabopyranose-28-norursol-12, 17-diene, and the effective medicinal components have a structural formula. The preparation method comprises the following steps of: 1. pulverizing charred sanguisorbae radix as a medicinal raw material, repeatedly extracting the medicinal raw material, and filtering to obtain a liquid extract; 2. dispersing the liquid extract obtained in step 1 with water, extracting with chloroform, and recovering solvent in the extract liquor to obtain an extract; 3. separating the extract obtained in step 2 by gel column chromatography, and leaching the obtained solid recrystal to obtain compound effective medicinal components; and 4. weighing 20-90% of effective medicinal component by weight ratios and other pharmaceutic adjuvants to prepare the medicine. The medicine has good effect on treating breast cancer, and can substitute for oral western medicines taken in duration of chemotherapy after an operation.
Description
Technical field
The present invention relates to medicine, is a kind of medicine for the treatment of breast carcinoma and preparation method thereof.
Background technology
Breast carcinoma is a kind of sickness rate disease with high, and according to the preliminary statistics, nearly 10 annual morbidities are ascendant trend gradually.The method of treatment breast carcinoma is medicine and operation at present, Most patients needs operative treatment, chemotherapy is a kind of Therapeutic Method preferably after the ocal resection, no matter Drug therapy still is the medicine that postoperative chemotherapy was taken in the phase, effectively medicine generally is Western medicine, yet the side effect of Western medicine proves very tangible through clinical.Though the Chinese medicine of treatment breast carcinoma is arranged in the disclosed data,, there are not data to show that it is evident in efficacy as yet.Therefore, in order to reduce the toxic and side effects that the patient with breast cancer takes Western medicine, this area is little in continuous research toxic and side effects always for many years, and the medicine of treatment breast carcinoma evident in efficacy is in the hope of reducing the dose of Western medicine.
Summary of the invention
The purpose of this invention is to provide a kind of medicine for the treatment of breast carcinoma and preparation method thereof, it is used for the treatment of breast carcinoma, makes its therapeutic effect good, and Western medicine for oral use in the alternative operation back chemotherapy phase.
The present invention is achieved through the following technical solutions for achieving the above object: a kind of medicine for the treatment of breast carcinoma is characterized in that: comprise that the medicine active ingredient is: 3
β-oxygen-α-L arabopyranose base-28-nor-ursol-12, the medicament that 17-diene and pharmaceutic adjuvant are made, medicine active ingredient by weight percentage is that 1%-90%, pharmaceutic adjuvant are 10%-99%, 3
β-oxygen-α-L arabopyranose base-28-nor-ursol-12, the structural formula of 17-diene is:
Described pharmaceutical formulation is a tablet, and the medicine active ingredient of tablet is that 20%-70%, pharmaceutic adjuvant are 30%-80%.
Described pharmaceutical formulation is a capsule, and capsular medicine active ingredient is that 20%-90%, pharmaceutic adjuvant are 10%-80%.
Described pharmaceutical formulation is aqueous injection or freeze dried powder, and the medicine active ingredient is that 1%-5%, pharmaceutic adjuvant are 95%-99%.
Described pharmaceutical formulation is powder or granule, and medicine active ingredient 10%-20%, pharmaceutic adjuvant are 80%-90%.
A kind of preparation method for the treatment of the medicine of breast carcinoma of the present invention may further comprise the steps:
1. get charred Radix Sanguisorbae and pulverize the back and be medicine material, add the methanol or the ethanol of ten times of amounts of raw material, or aqueous alcohols, room temperature or be heated to 60 ℃-90 ℃ extracted 1-24 hours, repeated to extract 1-3 times, filtered, and filtrate is the concentrated fluid extract that obtains under normal pressure or decompression;
2. with step 1. in fluid extract with 5-10 times of weight aqueous dispersion, with the extraction of amount of water 1/3 volumes of acetic acid ethyl ester, but re-extract 5-8 time, with extract normal pressure or decompression and solvent recovery, must extractum;
3. step extractum is 2. carried out column chromatography for separation, adopt chloroform-methanol system gradient elution, the 87:13 eluting is partly merged, obtain chemical compound 3 through Sephedax-LH 20 gel filtration chromatography separation and purification again by thin layer chromatography
β-oxygen-α-L arabopyranose base-28-nor-ursol-12, the 17-diene;
4. get 3 by weight
β-oxygen-α-L arabopyranose base-28-nor-ursol-12,17-diene 1%-90%, pharmaceutic adjuvant 10%-99% make medicament according to the conventional preparation method of medicament.
The structural formula of medicine active ingredient of the present invention, providing quasi-molecular ion peak m/z with high-resolution fast atom bombardment mass spectrometry is 541.3892[M+H]
+(C
34H
53O
5, value of calculation: 541.3888), determine that its molecular formula is C
34H
52O
5Infrared spectrum (potassium bromide) cm-1:3484(OH) 1388(CH, the saturated C-H of 2936(), 1452,
3), 1090(C-O).Proton nmr spectra shows 5 the unimodal signal δ of methyl 0.91(H-26), 0.97(H-25), 1.01(H-27), 1.07(H-24), 1.33(H-23) and 2 bimodal signal 0.84(H-29 of methyl, 3H, d, J=8.3Hz), 0.95(H-30,3H, d, J=6.9Hz), pointing out this chemical compound is pentacyclic triterpenoid.Also show a hydrogen signal δ 3.30(H-12 on company's oxygen carbon, 1H, dd, J=11.7 is 4.4Hz) with an alkene hydrogen signal δ 5.70(H-12, m).δ 4.79(1H, d J=7.04Hz), is the terminal hydrogen signal of arabinose, other proton signal is at 3.8 ~ 5.0ppm on the sugar.Nuclear magnetic resonance, NMR charcoal spectrum shows 4 olefinic carbon characteristic signal δ 117.4(C-12), δ 128.9(C-17), δ 133.4(C-18) with 137.5(C-13) and sugared outside 3 oxygen carbon signal δ of company 88.7 of low field displacement because of being connected, also have 5 company's oxygen carbon signals of sugar.
13The concrete numerical value of C-NMR sees the following form.
Nuclear magnetic resonance, NMR charcoal spectrum shows the signal after δ 88.7 is for the displacement of aglycon C-3 generation glycosidation, infer that chemical compound has sugar to be connected on 3 oxygen of aglycon, the relevant spectrum of heteronuclear multiple bond (HMBC spectrum) demonstration arabinose terminal hydrogen (δ 4.79) and aglycon C-3(δ 88.7) have relevantly, illustrate that arabinose is connected 3 of aglycon.The glycosidic bond configuration of sugar contrasts according to the coupling constant of terminal hydrogen and with data in literature, is defined as а-L configuration respectively.
Make C, the H ownership of chemical compound be confirmed that concrete numerical value sees the following form through the relevant spectrum of heteronuclear multiple bond (HMBC spectrum), heteronuclear Multiple-Quantum Coherences spectrum (HMQC spectrum).So determine the structure of this chemical compound, promptly 3
β-oxygen-α-L arabopyranose base-28-nor-ursol-12, the 17-diene.
(solvent is dimethyl sulfoxide-d to the nuclear magnetic resonance, NMR charcoal spectrum of table 1 chemical compound
6) and undistorted polarization transfer enhancing spectrum (DEPT spectrum) data
Medicine active ingredient of the present invention derives from charred Radix Sanguisorbae, and charred Radix Sanguisorbae has blood coagulation anastalsis preferably, holds back the skin ulcer effect.The applicant discovers, 3 in the charred Radix Sanguisorbae
β-oxygen-α-L arabopyranose base-28-nor-ursol-12, the 17-diene has the effect of significant its growth of inhibition to breast tumor cell, and can also suppress the formation of breast tumor new vessels, thereby provides fabulous basis for treating breast carcinoma.
Experiment shows 3
β-oxygen-α-L arabopyranose base-28-nor-ursol-12, the 17-diene has significant pharmacological action.
1, antitumor
The active ingredient of medicine of the present invention is a ursane type pentacyclic triterpene glycosides compound, and ursolic acid (ursolic acid) is the representative composition of this compounds.Ursolic acid is a broad-spectrum antitumoral compounds, external to the toxic effect of kinds of tumor cells.Ursolic acid not only can suppress growth of tumour cell, and can also suppress tumor neovasculature formation.
Experiment material:
The strain of human breast carcinoma MCF-7 cell.
Cultural method:
Human breast cancer cell MCF-7 is in the DMEM(that contains 10% hyclone culture medium that contains each seed amino acid and glucose) in adopt open monolayer adherence to cultivate, condition of culture is 37 degrees centigrade, 5% carbon dioxide, saturated humidity, when treating that cell grows to 80% concentration, 0.25% trypsinization, 1 culture fluid of replacing in per 3 days.Add and tried preceding 7 days of thing and cell is changed into after with phosphate buffer (PBS) washing contain 10% and go to cultivate among the no phenol red DMEM of estrogen hyclone, to exhaust the estrogen that stores in the cell.
Thiazolyl blue (MTT) experiment:
The MCF-7 cell inoculation that to cultivate 7 days in going the estrogen culture medium is in 96 orifice plates, and cell inoculation concentration is 5 000/hole.Cultivate and treated in 12 hours to discard old culture medium behind the cell attachment, what every hole added that 200 microlitres contain that each concentration tried thing goes the estrogen culture medium.(DMSO) is the solvent control group with 0.1% dimethyl sulfoxide, establishes 8 dosage groups, every group of 3 parallel samples.Cultivate and add Thiazolyl blue (MTT) solution 20 microlitres/hole after 48 hours, continue to hatch and stop after 4 hours cultivating, PBS washing 3 times, every hole adds 150 microlitre dimethyl sulfoxide, vibrated 10 minutes, survey each hole absorbance (A) value in wavelength 490 nanometers on the enzyme-linked immunosorbent assay instrument, the result represents with each x ± s that organizes 5 hole absorbances.The survival rate of calculating MCF-7 cell under the variable concentrations effect.
Cell survival rate (%)=experimental group absorbance/normal group absorbance * 100%
As shown in Figure 1, medicine active ingredient of the present invention has stronger inhibitory action to the growth of human breast cancer cell MCF-7, and show certain dose-dependence, at 0.1 and 0.01 mM/when rising, the inhibitory action of pair cell is the strongest, suppression ratio is about in the of 90%, in 0.001 lower mM/also have when rising good inhibitory effect.
Medicine of the present invention shows that through zoopery breast carcinoma is had extremely significant therapeutical effect;
Medicine of the present invention is as follows to the therapeutical effect zoopery of breast cancer cell MCF-7 tumor-bearing mice:
1, experiment material:
Human breast carcinoma MCF-7.Nude mice, female, body weight 20 ± 2 grams (Shandong University's animal center, laboratory animal license number SCXK Shandong 20030004).
Be subjected to reagent thing 3
β-oxygen-α-L arabopyranose base-28-nor-ursol-12,17-diene injection, normal saline is diluted to desired concn.
2, experimental technique:
The breast cancer cell of taking the logarithm and growing, under aseptic condition, with the fat pad of tumor cell inoculation in nude mouse left side second nipple, inoculum concentration is 1 * 10 with 1 milliliter of syringe
6/ only; Treat into (the long and short footpath of tumor is greater than 1 millimeter * 1 millimeter) begin treatment after the tumor.
To plant the tumor mice and be divided into 5 groups at random, positive group is cyclophosphamide, and blank group and model group are normal saline, administration every day 1 time, shared 3 weeks back drug withdrawal.After treating for 4 weeks, put to death laboratory animal, complete tumor resection is measured the tumor line of apsides, and gross tumor volume adopts ab
2/ 2 formula calculate (a is a tumor body major diameter, and b is a tumor body minor axis), peel off thymus, calculate tumour inhibiting rate, thymus index.
Tumour inhibiting rate=(matched group mean tumour volume-administration group mean tumour volume)/matched group mean tumour volume * 100%
Thymus index=thymic weight/body weight * 10
Compare * P＜0.05 * * P＜0.01 compares with normal group with model group: #P＜0.05 ##P＜0.01
Tried the growth that medicine of the present invention can suppress mice transplanted tumor, high, middle dosage group tumour inhibiting rate is respectively 58.11%, 42.57%, compares P＜0.01 or P＜0.05 with model group; The positive control cyclophosphamide can obviously suppress the growth of mouse tumor; but the mice body weight is obviously less than normal, and thymus index is obviously on the low side, and each dosage group of medicine of the present invention can not reduce mice body weight and thymus index; medicine of the present invention is less to the normal body influence, no obvious toxic-side effects.
Experiment shows that therefore, the patient can use various pharmaceutical dosage form of the present invention in breast cancer treatment because medicine of the present invention has significant effect to treatment breast carcinoma.Medicine of the present invention can also substitute the postoperative chemotherapy phase and unite the Western medicine of use, thereby thoroughly eliminates the toxic and side effects of Western medicine.
Description of drawings
Fig. 1 is the inhibitory action curve chart of medicine active ingredient of the present invention to human breast cancer cell MCF-7.
The specific embodiment
Embodiment
Medicine of the present invention is made medicament by medicine active ingredient and pharmaceutic adjuvant, and the structural formula of medicine active ingredient is 3
β-oxygen-α-L arabopyranose base-28-nor-ursol-12, the 17-diene
Medicine active ingredient by weight percentage is that 1%-90%, pharmaceutic adjuvant are 10%-99%, and medicine of the present invention can be made various dosage forms, as: injection: aqueous injection, freeze dried powder, tablet, capsule, granule, powder or oral liquid.
Described pharmaceutical formulation is a tablet, and the medicine active ingredient of tablet is that 20%-70%, pharmaceutic adjuvant are 30%-80%.
Described pharmaceutical formulation is a capsule, and capsular medicine active ingredient is that 20%-90%, pharmaceutic adjuvant are 10%-80%.
Described pharmaceutical formulation is aqueous injection or freeze dried powder, and the medicine active ingredient is that 1%-5%, pharmaceutic adjuvant are 95%-99%.
Described pharmaceutical formulation is powder or granule, and medicine active ingredient 10%-20%, pharmaceutic adjuvant are 80%-90%.
The preparation method of medicine of the present invention is to adopt charred Radix Sanguisorbae to extract the medicine active ingredient earlier, is prepared into required medicament according to conventional pharmaceutical methods then, may further comprise the steps:
1. get charred Radix Sanguisorbae and pulverize the back and be medicine material, add the methanol or the ethanol of ten times of amounts of raw material, or aqueous alcohols, room temperature or be heated to 60 ℃-90 ℃ extracted 1-24 hours, repeated to extract 1-3 times, filtered, and filtrate is the concentrated fluid extract that obtains under normal pressure or decompression;
2. with step 1. in fluid extract with 5-10 times of weight aqueous dispersion, with the extraction of amount of water 1/3 volumes of acetic acid ethyl ester, but re-extract 5-8 time, with extract normal pressure or decompression and solvent recovery, must extractum;
3. step extractum is 2. carried out column chromatography for separation, adopt chloroform-methanol system gradient elution, the 87:13 eluting is partly merged, obtain chemical compound 3 through Sephedax-LH 20 gel filtration chromatography separation and purification again by thin layer chromatography
β-oxygen-α-L arabopyranose base-28-nor-ursol-12, the 17-diene;
4. get 3 by weight percentage
β-oxygen-α-L arabopyranose base-28-nor-ursol-12,17-diene 1%-90%, pharmaceutic adjuvant 10%-99%,, make medicament according to the conventional preparation method of medicament.
Illustrate several dosage forms:
One, aqueous injection:
1. contain medicine effective ingredient 1%, all the other are adjuvant
1000 milliliters
3 β-oxygen-α-L arabopyranose base-28-nor-ursol-12,17-diene 10 grams, 10 milliliters of Tween 80s, sodium chloride 8 grams.
Get 3 β-oxygen-α-L arabopyranose base-28-nor-ursol-12,17-diene 10 grams, add 10 milliliters of Tween 80s, 250 milliliters of waters for injection, heating for dissolving, filter, add 10% sodium carbonate acid adjustment basicity, add sodium chloride to 7.0-7.5, add injection water to 1000 milliliter, G3 sintered filter funnel (glass) filters, packing, embedding, 100 degrees centigrade of flowing steam sterilizations 30 minutes, be sub-packed in 1 milliliter of ampoule bottle, every contains 3 β-oxygen-α-L arabopyranose base-28-nor-ursol-12,10 milligrams of 17-diene.
2. contain medicine effective ingredient 2.5%, all the other are adjuvant
3 β-oxygen-α-L arabopyranose base-28-nor-ursol-12,17-diene 25 grams, 10 milliliters of Tween 80s, sodium chloride 8 grams.
Get 3 β-oxygen-α-L arabopyranose base-28-nor-ursol-12,17-diene 25 grams, add 10 milliliters of Tween 80s, 250 milliliters of waters for injection, heating for dissolving, filter, add 10% sodium carbonate acid adjustment basicity, add sodium chloride to 7.0-7.5, add injection water to 1000 milliliter, G3 sintered filter funnel (glass) filters, packing, embedding, 100 degrees centigrade of flowing steam sterilizations 30 minutes, be sub-packed in 1 milliliter of ampoule bottle, every contains 3 β-oxygen-α-L arabopyranose base-28-nor-ursol-12,25 milligrams of 17-diene.
3. contain medicine effective ingredient 5%, all the other are adjuvant
3 β-oxygen-α-L arabopyranose base-28-nor-ursol-12,17-diene 50 grams, 10 milliliters of Tween 80s, sodium chloride 8 grams.
Get 3 β-oxygen-α-L arabopyranose base-28-nor-ursol-12,17-diene 50 grams, add 10 milliliters of Tween 80s, 250 milliliters of waters for injection, heating for dissolving, filter, add 10% sodium carbonate acid adjustment basicity, add sodium chloride to 7.0-7.5, add injection water to 1000 milliliter, G3 sintered filter funnel (glass) filters, packing, embedding, 100 degrees centigrade of flowing steam sterilizations 30 minutes, be sub-packed in 1 milliliter of ampoule bottle, every contains 3 β-oxygen-α-L arabopyranose base-28-nor-ursol-12,50 milligrams of 17-diene.
Two, capsule:
1, contain medicine effective ingredient 20%, all the other are adjuvant
1000
3 β-oxygen-α-L arabopyranose base-28-nor-ursol-12,17-diene 40 grams, microcrystalline Cellulose 80 grams, lactose 80 grams, magnesium stearate 1 gram.
Get 3 β-oxygen-α-L arabopyranose base-28-nor-ursol-12,17-diene, microcrystalline Cellulose, lactose, magnesium stearate, mixing, encapsulated, every heavy 0.2 gram contains 3 β-oxygen-α-L arabopyranose base-28-nor-ursol-12,40 milligrams of 17-diene.
2, contain medicine effective ingredient 50%, all the other are adjuvant
1000
3 β-oxygen-α-L arabopyranose base-28-nor-ursol-12,17-diene 100 grams, microcrystalline Cellulose 50 grams, lactose 50 grams, magnesium stearate 1 gram.
Get 3 β-oxygen-α-L arabopyranose base-28-nor-ursol-12,17-diene, microcrystalline Cellulose, lactose, magnesium stearate, mixing, encapsulated, every heavy 0.2 gram contains 3 β-oxygen-α-L arabopyranose base-28-nor-ursol-12,100 milligrams of 17-diene.
3, contain medicine effective ingredient 70%, all the other are adjuvant
1000
3 β-oxygen-α-L arabopyranose base-28-nor-ursol-12,17-diene 140 grams, microcrystalline Cellulose 30 grams, lactose 30 grams, magnesium stearate 1 gram.
Get 3 β-oxygen-α-L arabopyranose base-28-nor-ursol-12,17-diene, microcrystalline Cellulose, lactose, magnesium stearate, mixing, encapsulated, every heavy 0.2 gram contains 3 β-oxygen-α-L arabopyranose base-28-nor-ursol-12,140 milligrams of 17-diene.
4, contain medicine effective ingredient 90%, all the other are adjuvant
1000
3 β-oxygen-α-L arabopyranose base-28-nor-ursol-12,17-diene 180 grams, microcrystalline Cellulose 20 grams, magnesium stearate 1 gram.
Get 3 β-oxygen-α-L arabopyranose base-28-nor-ursol-12,17-diene, microcrystalline Cellulose, lactose, magnesium stearate, mixing, encapsulated, every heavy 0.2 gram contains 3 β-oxygen-α-L arabopyranose base-28-nor-ursol-12,180 milligrams of 17-diene.
Three, powder: 100 bags
1, contain medicine effective ingredient 10%, all the other are adjuvant
3 β-oxygen-α-L arabopyranose base-28-nor-ursol-12,17-diene 5 grams, lactose 250 grams, starch 245 grams.
Get 3 β-oxygen-α-L arabopyranose base-28-nor-ursol-12,17-diene, lactose, starch, porphyrize, mixing sieves, subpackage, every bag weighs 5 grams, contains 3 β-oxygen-α-L arabopyranose base-28-nor-ursol-12,50 milligrams of 17-diene.
2, contain medicine effective ingredient 20%, all the other are adjuvant
3 β-oxygen-α-L arabopyranose base-28-nor-ursol-12,17-diene 10 grams, lactose 250 grams, starch 240 grams.
Get 3 β-oxygen-α-L arabopyranose base-28-nor-ursol-12,17-diene, lactose, starch, porphyrize, mixing sieves, subpackage, every bag weighs 5 grams, contains 3 β-oxygen-α-L arabopyranose base-28-nor-ursol-12,100 milligrams of 17-diene.
Four, tablet:
1, contains medicine effective ingredient 20%, adjuvant 80%
1000
Chemical compound 3 β-oxygen-α-L arabopyranose base-28-nor-ursol-12,17-diene 40 grams, starch 120 grams, starch slurry (100 grams per liter) 40 grams, magnesium stearate 1 gram.
Chemical compound 3 β-oxygen-α-L arabopyranose base-28-nor-ursol-12,17-diene, adding starch mixing, add starch slurry system soft material, cross the sieve series grain No. two, dry 3 hours, No. two sieve granulate, add magnesium stearate mixing tabletting, every heavy 0.2 gram contains chemical compound 3 β-oxygen-α-L arabopyranose base-28-nor-ursol-12,40 milligrams of 17-diene.
2, contain medicine effective ingredient 40%, adjuvant 60%:
1000
Chemical compound 3 β-oxygen-α-L arabopyranose base-28-nor-ursol-12,17-diene 80 grams, starch 60g, starch slurry (100 grams per liter) 40 grams, magnesium stearate 1 gram.
Chemical compound 3 β-oxygen-α-L arabopyranose base-28-nor-ursol-12,17-diene, adding starch mixing, add starch slurry system soft material, cross the sieve series grain No. two, dry 3 hours, No. two sieve granulate, add magnesium stearate mixing tabletting, every heavy 0.2 gram contains chemical compound 3 β-oxygen-α-L arabopyranose base-28-nor-ursol-12,80 milligrams of 17-diene.
3, contain medicine effective ingredient 70%, adjuvant 30%:
1000
Chemical compound 3 β-oxygen-α-L arabopyranose base-28-nor-ursol-12,17-diene 140 grams, starch 20 grams, starch slurry (100 grams per liter) 40 grams, magnesium stearate 1 gram.
Chemical compound 3 β-oxygen-α-L arabopyranose base-28-nor-ursol-12, the 17-diene adds the starch mixing, add starch slurry system soft material, cross the sieve series grain No. two, dry 3 hours, No. two sieve granulate, add magnesium stearate mixing tabletting, every heavy 0.2 gram contains chemical compound 3 β-oxygen-α-L arabopyranose base-28-nor-ursol-12,140 milligrams of 17-diene.
Claims (5)
1. a medicine for the treatment of breast carcinoma is characterized in that: comprise that the medicine active ingredient is: 3
β-oxygen-α-L arabopyranose base-28-nor-ursol-12, the medicament that 17-diene and pharmaceutic adjuvant are made, medicine active ingredient by weight percentage is that 1%-90%, pharmaceutic adjuvant are 10%-99%, 3
β-oxygen-α-L arabopyranose base-28-nor-ursol-12, the structural formula of 17-diene is:
2. a kind of medicine for the treatment of breast carcinoma according to claim 1 is characterized in that: described pharmaceutical formulation is a tablet, and the medicine active ingredient of tablet is that 20%-70%, pharmaceutic adjuvant are 30%-80%.
3. a kind of medicine for the treatment of breast carcinoma according to claim 1 is characterized in that: described pharmaceutical formulation is a capsule, and capsular medicine active ingredient is that 20%-90%, pharmaceutic adjuvant are 10%-80%.
4. a kind of medicine for the treatment of breast carcinoma according to claim 1 is characterized in that: described pharmaceutical formulation is aqueous injection or freeze dried powder, and the medicine active ingredient is that 1%-5%, pharmaceutic adjuvant are 95%-99%.
5. a kind of medicine for the treatment of breast carcinoma according to claim 1 is characterized in that: described pharmaceutical formulation is powder or granule, and medicine active ingredient 10%-20%, pharmaceutic adjuvant are 80%-90%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105637573A CN102000099B (en) | 2009-12-02 | 2010-11-29 | Medicine for treating breast cancer and preparation method thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910310777.7 | 2009-12-02 | ||
| CN200910310777 | 2009-12-02 | ||
| CN2010105637573A CN102000099B (en) | 2009-12-02 | 2010-11-29 | Medicine for treating breast cancer and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102000099A CN102000099A (en) | 2011-04-06 |
| CN102000099B true CN102000099B (en) | 2011-12-07 |
Family
ID=43807967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010105637573A Expired - Fee Related CN102000099B (en) | 2009-12-02 | 2010-11-29 | Medicine for treating breast cancer and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102000099B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1174729A (en) * | 1997-07-18 | 1998-03-04 | 迟经惠 | Ointment for mastocarcinoma |
| CN1239663A (en) * | 1998-06-18 | 1999-12-29 | 陈大明 | Chinese medicine preparation for treating rectum cancer, colon cancer and breast cancer |
| CN101085184A (en) * | 2007-06-18 | 2007-12-12 | 沈信堂 | Traditional Chinese medicine for treating breast cancer |
-
2010
- 2010-11-29 CN CN2010105637573A patent/CN102000099B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1174729A (en) * | 1997-07-18 | 1998-03-04 | 迟经惠 | Ointment for mastocarcinoma |
| CN1239663A (en) * | 1998-06-18 | 1999-12-29 | 陈大明 | Chinese medicine preparation for treating rectum cancer, colon cancer and breast cancer |
| CN101085184A (en) * | 2007-06-18 | 2007-12-12 | 沈信堂 | Traditional Chinese medicine for treating breast cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102000099A (en) | 2011-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103599148B (en) | Husky fluffy extractive of general flavone and its preparation method and application | |
| CN101279964B (en) | Guaiane type sesquiterpenes, preparation and medical use thereof | |
| CN102068535A (en) | Immature bitter orange or bitter orange total flavonoids extract prepared by ethanol reflux and extraction and application thereof | |
| CN101880306B (en) | Stauntonia brachyanthera Hand-Mazz saponins components as well as preparation method and application thereof | |
| US20050287230A1 (en) | Method of producing ginsenoside 20 (R)-Rh2 and composition of matter thereof | |
| CN101537036A (en) | Soap pod saponin extract as well as preparation method and application thereof | |
| CN103751225B (en) | The extracting method of Cordyceps militaris (L.) Link. antitumor component and application thereof | |
| CN101028322B (en) | Use of Maoliefengdou extract for preparing anti-cancer medicine | |
| CN102908340B (en) | Isolicoflavonol-containing antitumor drug and application thereof | |
| CN1775267A (en) | Kaikoujian extract, Its preparing method and use | |
| CN101948453B (en) | Novel NEO-clerodane typed diterpene compound and application thereof | |
| CN1919339B (en) | Cucurbitacin nano preparation comprising protein, preparation method and use thereof | |
| CN102357180A (en) | Traditional Chinese medicine composite for curing cancer and preparation method and application thereof | |
| CN103191143B (en) | New application of cardiac glycoside compound | |
| CN102000099B (en) | Medicine for treating breast cancer and preparation method thereof | |
| CN102008496B (en) | Medicament for treating breast cancer and preparation method thereof | |
| CN102028698B (en) | Medicine for treating colon cancer and preparation method thereof | |
| CN101077873B (en) | Novel NEO-clerodane type diterpene compound and application thereof | |
| CN102961384A (en) | Medical application of przewaquinone A | |
| CN102688248A (en) | Use of bufadienolide compound in preparing medicines for treating oral mucosal malignant tumors | |
| CN102000085B (en) | Medicament for treating breast cancer and preparation method thereof | |
| CN101810624B (en) | Medicament for treating colon cancer and preparation method thereof | |
| CN113637021B (en) | Active compound, extraction method and application thereof, pharmaceutical composition and application thereof | |
| CN103694248B (en) | Antitumor compound extracted from guttifer, and preparation method and application thereof | |
| CN114507265B (en) | New monoterpene glycoside compound in plant medicine Bailiangjin, and extraction and separation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111207 Termination date: 20201129 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |